Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study).

•BERNIE evaluated the role of bevacizumab in childhood/adolescent metastatic soft tissue sarcoma.•The addition of bevacizumab to the chemotherapy backbone appeared tolerable.•The primary end-point of event-free survival did not show statistically significant improvement.•These data do not support the use of bevacizumab in metastatic RMS.